Back

Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering agents: review, meta-analysis, efficacy, and clinical outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Harshawardhan Dhanraj Ramteke

Chimur (India)

6 More presentations in this session

Presentation thumbnail
GLP-1 receptor agonist decreases VLDL-induced lipid accumulation in cardiomyocyte
Mr J. Chang (Kaohsiung, TW)
Abstract Slides Video
Presentation thumbnail
Real-world use of bempedoic acid for ASCVD risk reduction in a rural UK primary care practice: Analysing trends in LDL-C reduction, adherence, and ESC target attainment
Mrs M. Donaldson (Louth, GB)
Abstract Slides Video
Presentation thumbnail
Heterogeneous biomarker responses to CETP inhibitors: a phase 3 trials systematic review and network meta-analysis
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Class effects of subcutaneous lipoprotein(a)-lowering therapies: a systematic review and meta-analysis
Doctor M. Dogan (Greenville, US)
Abstract Slides Video
Presentation thumbnail
Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering agents: review, meta-analysis, efficacy, and clinical outcomes

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Upfront combination lipid-lowering therapy in acute coronary syndrome: a bayesian network meta-analysis of low-density lipoprotein cholesterol reduction and major adverse cardiovascular events
31 August 2026
thumbnail
Congress Presentation
Efficacy and safety of oral PCSK9 inhibitors in adults with hypercholesterolemia: a systematic review and meta-analysis with trial sequential analysis
28 August 2026
thumbnail
Congress Presentation
Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis
1 September 2025
thumbnail
Congress Presentation
Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources